ReviewFocus (American Psychiatric Publishing)2023
Pharmacologic Approaches to Suicide Prevention.
Review in Focus (American Psychiatric Publishing), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07120477 (Esketamine Versus Crisis Response Planning Versus Enhanced Treatment as Usual for Suicide Prevention), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Esketamine Versus Crisis Response Planning Versus Enhanced Treatment as Usual for Suicide Prevention: A Pragmatic Randomized Trial in a Brazilian Municipality (SAVE)
Who cites it
10 citing papers in PubMed, 20 citations in OpenAlex.
- Suicide attempt risk factors in individuals with psychiatric disorders and multi-affected families: a network analysis.Npj mental health research · 2026Article
- Targeting Psychological Pain After a Suicide Attempt: Scoping Review and Intervention Protocol.Journal of clinical medicine · 2026Review
- Exploring the effects of pharmacological treatments on suicidality in children and adolescents: a structured review of the literature and narrative synthesis.EClinicalMedicine · 2026Review
- Exploring the Link Between Suicidal Concern and Pharmacotherapy in Adolescents: Evidence from a Clinical Cohort.Journal of clinical medicine · 2025Article
- Context, Timing and Individualized Care: A Realist Evaluation of Safety Planning for Individuals Living with Suicide-Related Thoughts and Behaviours, Their Families and Friends and Service Providers.Journal of clinical medicine · 2025Article
- ["Assisted Suicide"-A Case Report on Assisted Suicide in the Context of Mental Illnesses].Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater · 2025Article
- The Effectiveness of Transcranial Magnetic Stimulation in Suicidality: An Updated Systematic Review.medRxiv : the preprint server for health sciences · 2025Article
- Purinergic System Transcript Changes in the Dorsolateral Prefrontal Cortex in Suicide and Major Depressive Disorder.International journal of molecular sciences · 2025Article
- Prevention of suicidal behavior with lithium treatment in patients with recurrent mood disorders.International journal of bipolar disorders · 2024Review
- Antisuicidal Effect of Lamotrigine Augmentation in Treatment-Resistant Depression: A Case Report.Clinical neuropharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Suicide is a leading cause of death that is often preventable. This article reviews the role of medications in treating suicidal behavior and in preventing suicide. For an acute suicidal crisis, ketamine, and perhaps esketamine, are emerging as important tools. For patients with chronic suicidality, clozapine remains the only U.S. Food and Drug Administration (FDA) approved antisuicidal medication, and its use is predominantly for patients with schizophrenia and schizoaffective disorder. An abundance of literature supports the use of lithium among patients with mood disorders, including those with major depressive disorder. Despite the black box warning regarding antidepressants and suicide risk among children, adolescents, and young adults, antidepressants are widely used and remain helpful in reducing suicidal thoughts and behaviors, primarily among patients with mood disorders. Treatment guidelines focus on the importance of optimizing treatment of the psychiatric conditions known to be associated with suicide risk. For patients with these conditions, the authors recommend focusing on suicide as an independent treatment target and using an enhanced medication management strategy that includes maintaining a supportive, nonjudgmental therapeutic relationship; flexibility; collaboration; measurement-based care; consideration of combining medications with nonpharmacologic, evidence-based strategies; and ongoing safety planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.